Friday, September 4, 2015

This week in ePharma: Google updates health search database | Viagra is Re-branding!

Pin It Now!


Google search results for health symptoms search query
Here is another proof that Google is leading the digital health industry:
Yesterday Google made an announcement ("Now Google can help with updated health information") about the updates that the search engine is planning to integrate within the next five weeks as a follow up on the search explosion around the rare form of pneumonia outbreak that happened earlier last month. As part of the change, Google is planning to expand their medical conditions database and make it more accessible by taking a user straight to the conditions tab upon the search is performed. Over the next few weeks it is expected that Google's medical database will grow by almost 45% from 400 conditions to 900.

In the press release of September 2, the FDA announced that it has approved Varubi (rolapitant), the drug to soften the side effects from chemotherapy such as nausea and vomiting. These symptoms are common among patients undergoing chemical therapy. But aside from immediate side effects, Varubi aims to treat the delayed nausea and vomiting symptoms that tend to occur within 120 hours after the chemical treatment has been issued.

This is the second time Viagra is showing up in the news within the past few weeks, but this time Viagra is in a spotlight because of the re-branding efforts that Pfizer is implementing. The "Blue pill" is said to be soon available in a single package, which is supposed to make it more convenient to purchase and carry around. With the mission "A new way to take VIAGRA with you when you need it" the drug maker Pfizer is seizing an opportunity to present Viagra as a more portable and handy solution on the go.

The European Pharmaceutical Review Magazine has reported the results from the survey conducted by The Crown Records Management/Censuswide on data management. After surveying over 200 companies in the pharmaceutical sector, 60% of IT decision makers revealed that their company had lost important data. With the recent scandalous data breach of the Ashley Madison website, more and more key players in the pharma industry express their concerns over secure future of the doctor-patient data.


Stay tuned for our weekly news round up! 

Subscribe to our Blog or follow us on Twitter: @epharma

 

About the author: Ksenia Newton, a Digital Marketing Assistant at IIR USA, Pharma Division, who works on various aspects of the industry including social media, marketing analysis and media. She can be reached at knewton@iirusa.com

Tuesday, September 1, 2015

Free Webinar: Connecting Insights to Improve the Customer Experience

Pin It Now!
Technology has dramatically improved collaboration between sales and marketing, enabling companies to approach customers in a more consistent and impactful way across digital and personal channels.

Join the upcoming webinar hosted by Veeva entitled, “Connecting Insights to Improve the Customer Experience” to hear Biogen's case study about connecting insights across channels and data sources for more intelligent and personal engagement to fulfill its vision for true closed loop multichannel marketing. Register here: http://bit.ly/1hvpuly


The presenters for this webinar are Brian Cantwell, Associate Director, Marketing Technology and Paul Shawah Vice President, Product Marketing – Veeva Systems.

Brian Cantwell leads Biogen’s U.S. Marketing Technology team, where he is responsible for building and executing digital marketing capabilities that enable Biogen's U.S. brands to have more effective, efficient and engaging customer interactions through personal and non-personal channels.
Paul is responsible for global product marketing at Veeva Systems where he has held senior leadership roles since 2011. Before Veeva, Paul ran the Life Sciences business unit at SAP with responsibility for product strategy and solutions globally. Prior to SAP, Paul held product marketing leadership roles at Proscape and Siebe.

Space is limited, save your seat! http://bit.ly/1hvpuly

Want more on this topic? Attend ePharma 2016 taking place February 29-March 2 in NYC. ePharma facilitates the largest digital pharma marketing community to share the latest and greatest trends, marketplace needs, and evolving customer bases to reach our ultimate goal – harness new opportunities to build stronger, cost efficient marketing campaigns. For more information about the conference, visit the website: http://bit.ly/1Vu8j2Q

Cheers,
The ePharma Team
@ePharma
Epharmasummitblog.iirusa.com


Friday, August 28, 2015

This week in ePharma: Google Life Sciences joins the Digital Health Race and more!

Pin It Now!
Google search logo
Earlier this week Sergey Brin made an official announcement about the Google's life sciences team moving into a separate Life Sciences venture with its own CEO. These changes are a part of the company's recent reorganization. Life Sciences is aiming big at making progress in health tech sphere. Google Smart Contact lenses is currently the most well-known project under Life Sciences.



Digital health app connected to a mobile device, connected to a computer and a virtual doctor. mHealthComputers are to become more humanized. More and more research companies are working their way into reading human emotions and interpreting them digitally. The goal is to use the data to make health wearables more sensitive to an individual user and therefore increase the effectiveness of the devices. Affectiva is one of the companies conducting such research. With the statement "Leading global expert in emotion analytics and insights" Affective claims to have analyzed 2,756,949 faces to date.


Bayer Healthcare logo
Digital health accelerator program? Sure. Two words: Germany, Bayer. “Grants4Apps Accelerator” program funded by Bayer Healthcare will sponsor five digital health startups who focus their research around such topics as predicting behavior, improve health in the work place, patient empowerment and others. The five health tech companies for Grants4Apps Accelerator 2015 have already been chosen. Within the given 100 days the Bayer Healthcare program guarantees to provide mentorship by Bayer's experts, office space,  and funding of 50,000€.

Another health tech accelerator program is launching, this time locally, in Pittsburgh. A large nonprofit health and wellness company Highmark Health has built VITAL - a program that aims to speed up an approval process for healthcare innovators. The VITAL innovation program promises to simplify the whole procedure from submitting a proposal to its evaluation and funding, and therefore make new technologies available to consumers faster.

Stay tuned for our weekly news round up! 

Subscribe to our Blog or follow us on Twitter: @epharma

 

About the author: Ksenia Newton, a Digital Marketing Assistant at IIR USA, Pharma Division, who works on various aspects of the industry including social media, marketing analysis and media. She can be reached at knewton@iirusa.com

Friday, August 21, 2015

ePharma news: This August - The Ice Bucket Challenge is back | "Viagra" for women is about to hit the market and more

Pin It Now!
The ALS Ice Bucket Challenge is back with the hashtag #EveryAugustUntilACure
Do you remember the Ice Bucket Challenge that took over the world last year? A brilliant campaign that was initiated by ALS Association in hopes to raise money for the Lou Gehrig's disease research, went viral not just in the U.S. but globally as well. By the end of 2014 the ALS Association was able to raise $115 million dollars. This August the Ice Bucket Challenge is back, and the funds collected last year are partially allocated toward the Lou Gehrig's disease research project conducted by Biogen Inc. and the Columbia University Medical Center. Earlier this year Biogen announced a $30-million-dollars funding that the company has committed to (plus, $3.5 million dollars raised by the Ice Bucket Challenge promotion.) The project is said to monitor 1,500 patients with the disease through clinical trial in efforts to find the cure.

Addyi is a "female version" of the Viagra pill produced by Sprout Pharmaceuticals
A "female version" of Viagra has just been approved by the FDA. Addyi is the first of its kind drug aiming at treatment of sexual desire disorders (HSDD) in both genders. HSDD stands for hypoactive sexual desire disorder, and as stated on the FDA official page: "HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance. HSDD is acquired when it develops in a patient who previously had no problems with sexual desire." It's noteworthy that the drug manufacturer Sprout Pharmaceuticals has been previously turned down twice, because the benefits of Addyi were said to be outweighed by the side effects and the risks caused by taking the drug. The Addyi drug has been approved with a strong warning against taking it with alcohol and other drugs because of its potentially toxic effect on the organism, and it will only be available through certified medical professionals. 

This week Kite Pharma is on a news but unfortunately not for a break through research but because of one of the patient's death while in a blood cancer clinical trial. The LA Times reported, that during the conference call the Kite Pharma CEO Arie S. Belldegrun stated, "A clinical investigator of the study conducted an in-depth review of the death and concluded that this death was unrelated to our product."
Following the investigation the FDA allowed the Kita Pharma company to continue with clinical trials.

Bionic wearable-technology earbuds Here Active Listening from Dobbler Labs
Image courtesy: http://www.hereplus.me/
Earbuds that will turn down the noise volume around you including the sound of crying babies? - Yes, please! A wearable-technology startup Doppler Labs has invented a wireless earbuds device that aims at increasing and adjusting your hearing depending on your personal comfort level. With the mission "Change the Way We Hear the World" and the price tag of $199, Here Active Listening is targeting audiophiles first. The company has posted a testimony-video by Hans Zimmer, a world-famous Grammy-winning composer, who in his support to the Here Active Listening gadget stated, "The way we find our place in the world is through touch, eyes, and hugely - through ears. You want to be able to select what you hear. It's about having control of your life."


Stay tuned for our weekly news round up! 

Subscribe to our Blog or follow us on Twitter: @epharma

 

About the author: Ksenia Newton, a Digital Marketing Assistant at IIR USA, Pharma Division, who works on various aspects of the industry including social media, marketing analysis and media. She can be reached at knewton@iirusa.com

Friday, August 14, 2015

This week in ePharma: FDA issues a warning to K. Kardashian's promoted morning-sickness drug

Pin It Now!
FDA issues a warning to Diclegis, the morning-sickness drug promoted by Kim Kardashian
In the week of July 24th it was announced that Diclegis has partnered with Kim Kardashian in promotional efforts of the new morning-sickness drug. This week the FDA has issued a warning over K. Kardashian's drug promotion on social media. In particular, it was stated that there was a violation of the federal drug-promotion rules. The reality star has never mentioned any side effects in her testimonial statement favoring the drug on Instagram. On August 7th the FDA has posted a warning letter addressing the drug's and Kardashian's promotional efforts as misleading and indicating that the social post was submitted as a complaint to the OPDP Bad Ad Program, the program that was designed to monitor and supervise the truthfulness of the prescription drug advertising and promotional efforts.

Roche Pharma Research & Early Development has developed a smartphone app to continuously monitor changes in patients with Parkinson’s disease. The hopes are the app will be able to collect data that can significantly improve medicine development program in Parkinson’s disease. Currently the app is in Phase I trial run with the the help of Prothena, a late-stage clinical biotechnology company that focuses on discovery, development and commercialization of programs with aim of potential treatment of diseases.


With the team of researchers from Oxford, Cambridge and London with backgrounds in medicine, behavioral health, bioengineering, design, and software the startup Hinge Health has set a goal to improve the lower back pain for many employees who spend most of the day at their desks, and help their employers reduce absenteeism and health costs. Hinge Health has produced a program that consists of physiotherapy, personalized coaching, weight loss, ability to tracking progress, and peer support opportunity. The program is a package that includes sensor bands, a tablet computer with software, and a number of other accessories. Based in London, the Hinge Health startup is currently aiming at the US market.


FDA has lost a battle for off-label marketing if the claims are truthful.
On August 7th the federal judge of the Federal District Court in Manhattan Paul A. Engelmayer has ruled that off-label marketing can be done legally even if FDA has not approved for as long as the claims are truthful based on the First Amendment (Freedom of Speech.) This precedent sets the history, because in the past many companies have lost this fight in court and ended up paying large settlements.

Here you can read How to Recognize and Report Off-Label Pharmaceutical Marketing.


Stay tuned for our weekly news round up! 

Subscribe to our Blog or follow us on Twitter: @epharma

 

About the author: Ksenia Newton, a Digital Marketing Assistant at IIR USA, Pharma Division, who works on various aspects of the industry including social media, marketing analysis and media. She can be reached at knewton@iirusa.com

Wednesday, August 12, 2015

Take Your Pharma Sales and Marketing Strategy to the Next Level at PharmaNEXT

Pin It Now!
Innovative, growth-oriented pharma companies are creating integrated commercial strategies to sustain and grow market share. The major shift in the pharma marketplace needs a different operating model where sales and marketing teams must work together and leverage innovation, technology and analytics to develop new go-to-market strategies.

The brand new PharmaNEXT conference will address these changes with boot camps, visionary keynotes, interactive debates, a curated expo hall, and more.

Here’s a look at the innovative sessions formats you will experience at PharmaNEXT:

NEXTTalks: Speakers share progress and report on real life examples of applications, success and failures. Hear from best-in-class practitioners on how to leverage innovation, technology and analytics to create new, effective operating models.

Think Tanks: Attendees split up in open roundtable discussions each based on one industry challenge to solve. Attendees can rotate to join in multiple open discussions on pertinent industry topics.

Bootcamps: Hand-on sessions with tangible takeaways and instant ROI. Take a deep dive into the most relevant topics in the next generation of pharma’s commercial strategy.

Think Tank Recaps: Think Tank leads to share findings with each working group and create actionable solutions for implementation.

Download complete agenda for program details: http://bit.ly/1HGskJY

Join us for next generation strategies and solutions that await you at PharmaNEXT - the latest educational and networking experience focused on elevating your pharma commercial strategy to the next level.

Your future depends on how your respond to this change.

As a valued member of our LinkedIn community you get $100 off the current rate when you register using code XP2040blog:  http://bit.ly/1HGskJY

We hope to see you in Philadelphia this fall!

Cheers,
The Pharma Next 2015 Team
#PharmaNext
@ePharma
epharmasummitblog.iirusa.com


Friday, August 7, 2015

This week in ePharma: The Future is here: FDA o'kays the 3-D printed drug and more!

Pin It Now!
The Future is here! The biotech industry continues to explore the possibilities of 3-D print technology, and one of its latest developments is a 3-D-printed pill.

FDA approves the first 3D-printed drug
FDA gives a go to the first ever 3-D printed drug against epilepsy called SPRITAM. Some of the benefits of a 3-D-printed drug are the ability to manufacture the drugs with high dose of the active element levetiracetam in one dosage and to produce pills identical to one another making it easier for patients to swallow. As NPR stated the drug is expected to hit the market in 2016.




Yelp partners with ProPublica, to provide Yelp's users with with healthcare statistics on hospitals and clinics around in the US. ProPublica is a nonprofit organization based NYC whose mission is "Journalism in the Public Interest." ProPublica does investigative reporting in many fields include healthcare. What Yelp is aiming for is to be able to better navigate its users and help them make more conscious decisions regarding their health. The statistics will include such categories as the number of beds available at a hospital, wait times
and more.

The Next Web in its article "Can tech help overcome addiction?" explores a new trend in mobile app development - mobile health apps focused on creating bonds between people with similar challenges such as sobriety, past drug addiction and others. It's been documented that there's a strong relationship between isolation and addiction, therefore more and more tech start ups shift their attention toward building mobile health apps that provide support from communities of like-minded. One of such mobile health apps is called My Sober Life that aims to support young people in their path to sobriety.

It's been reported that Hospira's Symbiq Infusion System (an IV pump) has a security loop that allows unauthorized users to access the equipment remotely and control the dosage of drugs delivered. And while no security breaches has been revealed, the FDA issued a safety alert urging hospitals to stop using the system as a prevention measure.

 

Stay tuned for our weekly news round up! 

Subscribe to our Blog or follow us on Twitter: @epharma

 

About the author: Ksenia Newton, a Digital Marketing Assistant at IIR USA, Pharma Division, who works on various aspects of the industry including social media, marketing analysis and media. She can be reached at knewton@iirusa.com

Friday, July 31, 2015

This week in ePharma: Self-diagnosis with Wize Mirror and more!

Pin It Now!
The digital revolution is spreading across the pharma and medical industries faster and faster, cutting down the costs of services and the wait time along the way.

ePharma news: Opternative, a digital health company, just launched an app that you can use to take an eye exam at homeAnother bright star on the digital health horizon is Opternative, the company that just launched a $40 online eye exam that everyone can take at home has he/she got a computer, smartphone and Wi-Fi.
As stated by TechCrunch, Opternative today is the only approved online eye exam that if done successfully will issue eye glasses prescription that can be used as online as in your local eye glasses store. The downside is, Opternative cannot diagnose eye diseases, so it is highly recommended to still check with an eye doctor once in a while as a preventative measure.


More and more health devices enter our and become an essential part of lives. Here is another promising gadget that is aiming at diagnosing medical conditions by "scanning" a person's face in the mirror. The idea behind SEMEOTICONS a.k.a. Wize Mirror is to integrate a multi-sensory system into a hardware platform
that looks like a mirror. This hardware will be able to read individual faces, monitor changes in their statuses and provide tailored suggestions about nutrition, physical activity, and more thus creating a platform for self-monitoring.

The smart technology market has expanded dramatically in the last five years coming up with many from business to fitness and health - oriented devices. A South Korean startup Dot has decided to face the fact that there's a large market of visually impaired people, who have the same demands for health wearables but don't have an equal supply. The problem that Dot stated they are trying to solve is out of 285 million visually impaired people, 95% cannot read. The prices for e-braille readers are very appalling and count in thousands of dollars still, therefore most of that 95% stay illiterate. With that in mind, Dot has launched an affordable E-braille smartwatch for visually impaired people. Tech in Asia reports that Dot smartwatch (currently available in Asia only) will go on sale in the United States in December at a retail price of approximately US$300.

A new development in treating obesity: the FDA has just approved a new medical device for a non-surgical obesity treatment - Reshape. Reshape integrates a dual balloon technology, which when inserted orally into a patient's stomach creates a feeling of being full and thus significantly shrinks the portions of food consumed. Combined with special diet and exercises Reshape is said to have natural, promising lasting results. The med device official website also claims, that during the recent studies patients lost more than two times more weight with ReShape than with diet and exercise alone. Plus, they were able to keep most of the lost weight off even after the device has been removed six months later.

Stay tuned for our weekly news round up! 

Subscribe to our Blog or follow us on Twitter: @epharma

 

About the author: Ksenia Newton, a Digital Marketing Assistant at IIR USA, Pharma Division, who works on various aspects of the industry including social media, marketing analysis and media. She can be reached at knewton@iirusa.com

Wednesday, July 29, 2015

Tap Into Insiders' Top Secrets to Success at PharmaNEXT, Plus Get $500 Off by July 31st

Pin It Now!
PharmaNEXT is proud to present Jane McGonigal, PhD, New York Times Bestselling Author and Author of SuperBetter - a revolutionary thinker, who will give you the insights on how to apply her award-winning out-of-the-box thinking to pharma.

Fast Company: "Top 100 Creative People in Business"
Oprah Winfrey for O Magazine: "20 Most Inspiring Women in the World"
MIT Technology Review: "Top 35 innovators changing the world through technology"
Business Week: "Top Ten Innovators to Watch"
Harvard Business Review: "Top 20 Breakthrough Ideas"

Whether you are trying to engage the patient or the physician, learn about both ends of the spectrum. These NEXTTalks feature life science professionals who will show you how to reach your evolving target customer and have your message resonate to achieve your desired outcome.

·         Leveraging our Insights for Better Physician Engagement: Jayne Gretz, Vice President, American Medical Association and Leslie Stokes, Senior Vice President for Physician Engagement, American Medical Association
·         Going from Brand Centric to Patient Centric from R&D to Commercialization: Anne C. Beal, MD, MPH
Chief Patient Officer, Center of Excellence for Patient Centricity, Sanofi 

Download complete agenda for details: http://bit.ly/1MtRtOA

Join the participating companies including: Sanofi, Bayer, Astellas, Merck & Co., Inc, Bristol-Meyers Squibb, Mylan, Biogen, Daiichi-Sankyo, AstraZeneca and many more for next generation strategies and solutions that await you at PharmaNEXT - the latest educational and networking experience focused on elevating your pharma commercial strategy to the next level.

Register by July 31st with code 00GKMH7ZD and save $400 off the standard rates. Plus use code XP2040blog and get an additional $100 off – that’s a $500 discount. Register here: http://bit.ly/1MtRtOA

Cheers, 
The Pharma Next 2015 Team
#PharmaNext
@ePharma
epharmasummitblog.iirusa.com




Friday, July 24, 2015

This week in ePharma: Diclegis partners with Kim Kardashian and more

Pin It Now!
The summer is at its full speed, and we are ready to present you with yet another portion of ePharma news of this week!

Would you trust a purple pill against headache? Could a green pill create more trust in you? With this concept in mind researchers decided to find out whether color and shape of pills affected the perception of effectiveness of the drug and people's expectations. As was reported in The Wall Street Journal, the participants of this online study judged pills of three different colors and in seven different shapes. As the result, the white pills were rated as the most affective, and the light green pills caused the participants to become skeptical in terms of its effectiveness in treating headache.




Celebrity buzz: Kim Kardashian is now endorsing Diclegis, also known as a morning sickness drug. Duchesnay USA, the drug maker, and the reality TV star have partnered together to help raise awareness around morning sickness symptom relief that K. Kardashian has allegedly suffered from during both of her pregnancies (until she tried Diclesis.) It's important to point out, that Diclegis is currently the only medication for treatment of nausea and vomiting during pregnancy that's been approved by FDA.

Researchers from Partners Connected Health, the Department of Pulmonology, Massachusetts General Hospital, and pediatric asthma group as a team effort have created a password - protected Facebook group to conduct a 12-month-long asthma study among teens 14-17 years old. Along with the tests researchers sent monthly reminders and important information regarding asthma. The study had an unprecedented engagement results of 79% in comparison to an average 18% of engagement. In the society which is driven by user-generated information, scientists find high engagement results hugely important for the future research and drug development purposes.


Allergan, Botox maker, launched a new internet campaign, #ActuallySheCan, targeting millennial women. According to The Guardian, women make up 62% of their market in the US. The premise of this campaign is to start engaging millennial women and build lifetime loyalty toward the Allergan pharma brands and products. ActuallySheCan is also a website that educates women on birth control and serves as a community space gamifying the user experience from "shemojime" option of creating a unique emoji with the user's face to "gimme the deets" - a program that allows to earn virtual coins to donate to a participating women's charity.

Stay tuned for our weekly news round up! 

Subscribe to our blog or follow us on Twitter: @epharma

 

About the author: Ksenia Newton, a Digital Marketing Assistant at IIR USA, Pharma Division, who works on various aspects of the industry including social media, marketing analysis and media. She can be reached at knewton@iirusa.com